Last updated: May 31, 2026
Executive summary: Inbrija (levodopa inhalation powder) is manufactured and supplied under licenses and supply arrangements tied to the brand’s FDA approval and the product’s contracted manufacturing network. The drug is commercialized in the US by Acorda Therapeutics’ successor organization (historically Acorda; later acquisition-linked ownership), while Inbrija’s inhalation powder production and packaging are performed by contracted drug product and packaging sites using approved processes. Supply continuity depends on the contract manufacturing network that executes the approved inhalation powder formulation and device-related packaging.
Who manufactures Inbrija (levodopa inhalation powder) and what contract manufacturers supply it?
Inbrija’s commercial supply is produced through a controlled set of FDA-approved manufacturing and packaging operations listed on the product’s FDA approval record and associated inspection history. For inhalation powders, supply typically hinges on three linked capabilities: (1) blending and milling to a controlled particle size distribution, (2) filling into inhalation-compatible capsules or unit-dose components, and (3) packaging that maintains moisture and airflow stability.
Featured snippet answer: Inbrija is supplied by a contract manufacturing and packaging network whose facilities are reflected in FDA listing for the approved product and its commercial packaging chain.
What parts of the supply chain are controlled for Inbrija?
Inbrija’s inhalation powder supply chain is governed by:
- API handling and any required intermediate steps (levodopa is typically sourced from established API suppliers and handled under approved compendial or DMF-linked controls).
- Finished dose manufacturing controls for powder uniformity, particle size distribution, and dose metering reproducibility.
- Unit-dose capsule filling, seal integrity, and stability packaging that mitigates moisture uptake.
- Labeling and distribution packaging for the US commercial market.
How to map Inbrija supply risk to manufacturing constraints
Inhalation powders concentrate risk in a small number of critical manufacturing steps:
- Milling and blending hold the tightest critical quality attributes (CQAs) for dose delivery uniformity.
- Packaging moisture barrier performance is a high-sensitivity failure mode.
- Any change to fill weight targets, capsule seal parameters, or device-adjacent packaging can trigger regulatory comparability requirements.
Which companies supply Inbrija to wholesalers and pharmacies in the US?
In the US, Inbrija is distributed through standard pharmaceutical wholesaler channels. The distributor identity is usually captured in drug listing and distribution records tied to the National Drug Code (NDC) and labeler details. The labeler or marketing authorization holder maintains contractual distribution arrangements, which can shift across geographies and time.
Featured snippet answer: Inbrija reaches the US market through labeled distribution by the product’s approved marketing authorization holder and affiliated logistics vendors, then through national wholesalers into pharmacy channels.
What NDC-level clues reveal about suppliers
For brand drugs like Inbrija, suppliers and manufacturing sites are best reconstructed via NDC-linked FDA product listing fields and the FDA approval and chemistry, manufacturing, and controls (CMC) package for the approved application. NDC specificity matters because a change in pack size or labeler can correspond to a different manufacturing-and-packaging configuration.
What suppliers provide the levodopa inhalation powder API and intermediates?
Inbrija uses levodopa as the active ingredient. The API supply chain can involve:
- Direct API manufacturers and their approved sites under DMF or ASMF arrangements (if used).
- API re-packagers or relabelers for internal QA/QC compatibility and logistics.
- Intermediate handling suppliers for specific crystallization or particle engineering steps.
Featured snippet answer: Inbrija’s API sourcing is supplied by levodopa manufacturers whose facilities are authorized under the product’s approved application controls.
Where API supply constraints show up in inhalation products
For inhalation powder systems, API supply is constrained not only by identity and assay but by:
- particle morphology and downstream blending compatibility
- polymorphic form control if relevant to dissolution behavior in the formulation
- impurity profiles and stability during blending and storage
How do you identify Inbrija’s approved manufacturing sites (site names, dosage forms, packaging types)?
For a complete, defensible supplier list suitable for licensing, procurement diligence, or litigation discovery, manufacturing site identity is tied to:
- the FDA approval record for Inbrija’s initial NDA/BLA submission and subsequent supplements
- current good manufacturing practice (cGMP) status and inspected site history
- product-specific listing fields that tie NDC presentation to manufacturing/packaging operations
Featured snippet answer: Identify Inbrija’s approved manufacturing and packaging sites by matching its current NDC presentation to FDA product listing and the corresponding approval application CMC manufacturing sections.
Why inhalation powder suppliers change less often than tablets
Inhalation powders have tighter and more complex CMC requirements than many oral solids:
- particle size and flow behavior require more validation work
- moisture barrier and capsule integrity must be validated for end-to-end product performance
As a result, supplier shifts usually occur through approved CMC supplements rather than short-term informal sourcing changes.
What supplier issues could disrupt Inbrija availability?
Supply interruption risk for Inbrija typically stems from:
- manufacturing capacity shortfalls at the contracted finishing and packaging site
- raw material constraints for levodopa or critical excipients used in powder blending
- stability or packaging line outages tied to moisture barrier performance
- regulatory holds tied to cGMP nonconformities at a specific facility
What procurement teams should monitor
- Batch release timelines and any backorder history for specific NDCs
- Lot-to-lot variation reports for key in-process controls
- Any announced FDA inspection outcomes or corrective action plans impacting manufacturing sites
How does Inbrija supplier landscape compare with other inhaled levodopa products?
Other levodopa delivery formats (including inhaled alternatives) may use different manufacturing networks, but the supply-chain logic remains similar:
- inhalation-capable finished dose manufacturing is a higher specialization activity than standard tablet or capsule filling
- unit-dose packaging and powder stability dominate supply bottleneck risk
Featured snippet answer: Compared with solid oral tablets, inhaled levodopa products rely on fewer, more specialized contract manufacturing and packaging capabilities, increasing dependency on specific facilities.
Key takeaways
- Inbrija’s supplier network is defined by the product’s FDA-approved manufacturing and packaging sites, executed by contract manufacturers under approved CMC processes.
- Supply risks cluster around inhalation powder finishing, capsule/unit-dose filling, and moisture barrier packaging performance.
- A precise supplier list requires NDC-level mapping to FDA product listing and the approval CMC manufacturing sections tied to the Inbrija brand.
FAQs
1) How can procurement verify which manufacturing sites produce Inbrija for a specific NDC?
By linking the NDC presentation to FDA product listing fields and the corresponding approved CMC manufacturing and packaging sections for that presentation.
2) What typically drives changes in suppliers for inhalation powder brands like Inbrija?
Approved CMC supplements reflecting changes in a contracted manufacturing or packaging site, or changes in packaging configuration that affect stability or dose performance.
3) What supply chain segment is the highest risk for Inbrija availability?
Finished-dose manufacturing and unit-dose packaging steps that control powder performance and moisture barrier integrity.
4) Can Inbrija be sourced from multiple finished-dose manufacturing sites at once?
Yes, but only if each site is covered by the approved CMC package for the specific NDC presentation and is producing under validated processes with batch release controls.
5) What due diligence matters most when qualifying new suppliers for Inbrija components?
Compatibility with approved formulation controls, validated particle size and blending parameters, impurity/stability requirements, and cGMP compliance for the specific step the supplier performs.
References (APA)
No sources were provided in the prompt, and I did not receive FDA label/manufacturing or NDC listing data necessary to cite accurately.
